2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Glioblastoma
80
Prostatic Neoplasms
57
Breast Neoplasms
54
Carcinoma, Non-Small-Cell Lung
53
Esophageal Neoplasms
48
Rectal Neoplasms
42
Lung Neoplasms
41
Squamous Cell Carcinoma of Head and Neck
33
Head and Neck Neoplasms
33
Brain Neoplasms
33
Gliosarcoma
31
Pancreatic Neoplasms
29
Uterine Cervical Neoplasms
28
Neoplasms
25
Glioma
24
Neoplasm Metastasis
23
Sarcoma
22
Oropharyngeal Neoplasms
21
Melanoma
19
Esophageal Squamous Cell Carcinoma
19
Astrocytoma
18
Adenocarcinoma Of Esophagus
15
Stomach Neoplasms
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Carcinoma, Squamous Cell
12
Urinary Bladder Neoplasms
11
Mouth Neoplasms
11
Lymphoma, Follicular
11
Central Nervous System Neoplasms
11
Carcinoma
11
Interventions
Carboplatin
7
Trastuzumab
6
Docetaxel
5
pembrolizumab
4
Paclitaxel
4
Oxaliplatin
4
Fluorouracil
4
Cytarabine
4
Cyclophosphamide
4
Azacitidine
4
pertuzumab
3
Radiotherapy
3
Observation
3
Neoadjuvant Therapy
3
Epirubicin
3
Endoscopy
3
Cisplatin
3
Chemoradiotherapy
3
Capecitabine
3
venetoclax
2
toripalimab
2
sargramostim
2
olaparib
2
durvalumab
2
cc-486
2
Tretinoin
2
Surgical Procedures, Operative
2
Standard of Care
2
Pemetrexed
2
Monatide (IMS 3015)
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Radiation
×
Clear all
NCT07472868
2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3
Not yet recruiting
394 enrolled